Korro Secures $85M Lifeline After Trial Setback

Got story updates? Submit your updates here. ›

Korro Bio, a Cambridge-based biotech company, has secured an $85 million private placement to extend its runway into late 2028. This comes after the company's lead candidate KRRO-110 missed projected protein levels in a recent trial, prompting a strategic pivot toward GalNAc-delivered programs and workforce reductions.

Why it matters

The funding will allow Korro to push forward with its next-generation RNA-editing candidates and move other liver-focused programs toward clinical data, despite the setback with its lead asset. This highlights the challenges small biotechs in Cambridge's life sciences ecosystem can face when a single clinical trial does not meet expectations.

The details

Korro has entered a subscription agreement to sell 4,501,928 shares of common stock at $11.11 per share and pre-funded warrants for another 3,148,836 shares, generating gross proceeds of about $85 million. The lead investor is Venrock Healthcare Capital Partners. This new funding, combined with $85.2 million in cash and marketable securities Korro had at year-end, is expected to support the company through upcoming clinical milestones.

• Korro's REWRITE study in alpha-1 antitrypsin deficiency showed its therapy could generate functional M-AAT protein, but did not boost total AAT to the company's protective threshold in the fall of 2025.
• Korro cut roughly 34% of its workforce in November 2025 after an earlier round of reductions in the spring, as part of a strategic reset.
• Korro expects the $85 million private placement to close on or about March 10, 2026.

What’s next

Investors and potential partners will be watching for the closing of the private placement, expected on or about March 10, 2026, as well as any near-term development-candidate nominations or IND filings that could validate Korro's new GalNAc delivery strategy.